Intelligent information management enables quality-by-design in pharmaceutical production
Zihan Zhu
Abstract
The pharmaceutical industry is undergoing a paradigm shift towards digitalization and smart manufacturing under the Pharma 4.0 framework, with a growing emphasis on integrating Artificial Intelligence (AI) into Quality-by-Design (QbD) principles. This study proposes an AI-powered information management framework to enhance predictive quality control, regulatory compliance, and operational efficiency in pharmaceutical production. The framework consolidates structured process and product datasets with unstructured regulatory documents, enabling comprehensive data integration and decision support. Machine learning and deep learning models were employed to predict critical quality attributes (CQAs) from CPPs, while natural language processing (NLP) was applied to manage regulatory documentation. Explainable AI (XAI) techniques, including SHAP and LIME, were integrated to ensure interpretability and compliance with ICH Q8–Q11 guidelines. Experimental evaluations demonstrated the superior predictive accuracy, robustness, and scalability of deep learning approaches compared to traditional QbD methods such as Design of Experiments (DoE) and regression. Statistical hypothesis testing confirmed that the observed improvements were significant (p < 0.01), while ablation studies highlighted the critical role of NLP, dimensionality reduction, and XAI modules in ensuring compliance and efficiency. Benchmarking results further established that the proposed framework outperforms conventional approaches in adaptability to high-dimensional, large-scale datasets, with deep learning models demonstrating resilience under noise, missing data, and process variability. The findings underscore the transformative potential of AI-powered QbD frameworks for advancing smart pharmaceutical production. By integrating predictive analytics, explainability, and regulatory alignment, the proposed approach provides a scalable and compliant pathway toward Pharma 4.0, enabling continuous improvement and patient-centric outcomes.